GlaxoSmithKline (GSK) offers support programs to patients with cancer in the United States or Puerto Rico. Through its Commitment to Access program, patients prescribed GSK medications potentially have access to free medicine, reimbursement support, or copay assistance. The programs differ in structure for federally insured, privately insured, and uninsured patients.
The following sections will assist healthcare professionals and payers by providing appropriate coding and billing information associated with the treatment of patients with breast cancer.
As the Centers for Medicare & Medicaid Services (CMS) continues its efforts to ensure that those who are enrolled in the Federal Health Insurance Marketplace (FHIM) meet eligibility requirements, the ripple effects of these efforts may be felt at medical practices nationwide.
Changes in our economy and healthcare system (ie, the Affordable Care Act, accountable care organizations, evolving reimbursement models) have given birth to a new member of the healthcare team: the financial advocate. Although many hospitals and large clinics have some form of patient advocates and nurse navigators, not all of these professionals are trained in the complex financial issues inherent to the care of treating a patient with cancer. Furthermore, many professionals are too thinly spread, and see too many patients to develop an expertise in advising on any single disease type.
The US Food and Drug Administration (FDA) recently took initial steps toward regulating laboratory-developed tests (LDTs). Used to select appropriate treatment for individual patients, LDTs are designed, made, and used within a single laboratory, and include genetic tests and tests used by clinicians to guide their patients’ treatment.
As today’s healthcare climate evolves, physicians and hospitals continue to explore options for alignment between private practices and healthcare systems. Interest in alignment perseveres despite a challenging healthcare environment, and economic, leadership, and structural issues should all be explored with due diligence prior to agreeing on a final arrangement. In this article, the issues of governance and compensation plans are explored as key elements for hospitals and physicians to consider as they work toward developing successful alignment plans.
The following clinical trials are currently recruiting participants with breast cancer for inclusion. Each trial description includes the NLM Identifier to use as reference with ClinicalTrials.gov.
Arzerra (Ofatumumab) Receives FDA Approval for Patients with Previously Untreated Chronic Lymphocytic Leukemia for Use in Combination with Chlorambucil
Chronic lymphocytic leukemia (CLL), the most common type of leukemia in adults, is a cancer that predominantly affects the B-cell lymphocytes. Normal B-cell lymphocytes originate in the bone marrow, develop in the lymph nodes, and fight infection by producing an immune response. In CLL, excess B-cells accumulate in the bone marrow and blood, where they crowd out healthy blood cells.
Once upon a time, there existed a town–gown divide in healthcare: a large academic center in one part of the state sought referrals from physicians in surrounding communities, but the physicians were reluctant to send too many referrals because often they would not get the patients back.
Every medical practice is at risk for a natural or man-made disaster. Those who have worked through a disaster will share their relief at having had a plan in place to get through it, or they may share, unfortunately, how much they wish they had developed a plan ahead of time.
Results 1 - 10 of 10